April 23rd 2024
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration
January 6th 2015Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Read More
CAR T-Cell Therapy CTL019 Demonstrates 92% Response Rate in Pediatric ALL
December 7th 2014The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
Strategies in Surveillance: Hepatocellular Carcinoma
October 27th 2014As with most cancers, early diagnosis and treatment of hepatocellular carcinoma (HCC) may result in more effective treatment and improved outcomes. Unfortunately, most patients with HCC are diagnosed at a late stage, when therapeutic options are limited and prognosis is poor.
Read More
First FDA Breakthrough Designation Granted to CAR Therapy
July 11th 2014The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
Targeting Radiotherapy in the Liver: SIR-Spheres®
June 23rd 2014The liver is a common site of metastatic recurrence for many tumors. For a minority of patients, surgical resection may be an option; however, most patients will not qualify for surgery due to insufficient liver functional reserve or other contraindications.
Read More
The Prognostic Value of CRP in HCC
May 21st 2014Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.
Watch
Microwave Ablation for the Treatment of Liver Cancer
April 3rd 2014Boris Kuvshinoff II, MD, MBA, associate professor, Division of Gastrointestinal/Endocrine Surgery, Department of Surgical Oncology, director, Liver and Pancreas Tumor Center, Roswell Park Cancer Institute, discusses microwave ablation therapy for the treatment of liver cancer.
Watch
LY2157299 as Treatment for Patients with Advanced HCC
March 21st 2014Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta receptor I (TGF-β1) kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium
Watch
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
Embolization Versus Embolization Plus Systemic Therapy in HCC
March 5th 2014Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective analysis that evaluated embolization versus embolization plus systemic therapy in patients with hepatocellular carcinoma and metastatic disease.
Watch
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
February 24th 2014Treatment with an inhibitor of TGF-β led to significant reductions in a prespecified biomarker that correlated with increased TTP and OS in patients with advanced HCC, according to results of a phase II clinical trial.
Read More
Whole-Genome Sequencing Identifies Actionable Mutations in HCC
January 17th 2014A research team at Cold Spring Harbor Laboratory in New York has succeeded in identifying the most common genetically altered genes and the major oncogenic drivers in hepatitis B virus-associated hepatocellular carcinoma (HCC).
Read More
Tivantinib and Regorafenib for the Treatment of Liver Cancer
January 9th 2014Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
Watch